castration - resistant prostate cancer, with or without metastases. Management M1 prostate cancer: impact of comorbidities and access to supportive therapies. Multidisciplinary management of prostate cancer, considering therapies that improve survival and quality of life. Surgeon's experience: determining factor in the success of prostate cancer surgery. Open and laparoscopic surgeries, excellent alternatives approach to robot-assistedsurgery. Robotic assisted laparoscopic prostatectomy: is here to stay! Novel techniques for robotic prostate surgery: Spectroscopy and fluorescence antI-PSMA Antibody. Impact of hypothermia on the preservation of nerve complex in the radicalprostatectomy. Extended Lymphadenectomywith Radical prostatectomy after Neoadjuvant Hormonal Therapy: outcomes Salvage Lymphadenectomypost- radical prostatectomy New nomograms and algorithms to predict recurrence in high-risk prostatecancer. Quality of life. Surviving to prostate cancer. Management of recurrence, urinary incontinence and erectile dysfunction.
Biomarkers, the new frontier. Tumormarkers.
Benefits and harms of the PSA test for the detection of prostate cancer. Lessons learned from the REDUCE clinical study. Active surveillance: who, when, how and withwhat? Management of Localized Prostate Cancer. Optimizing prostate cancer diagnosis: Trans-perineal, Ultrasound guided trans-rectal and multiparametric MRI/ultrasound fusion guided transrectal biopsy. Value of Ga-PSMA PET / CT for the clinical management of patients with prostatecancer. Prognosisof lowGleasonscore in patients under active surveillance.
SYMPOSIUM. PROSTATE CANCER. II MEDICAL AND SURGICAL TREATMENT. Guidelines for themanagement of localized prostate cancer. Radiotherapy and Chemotherapy in Prostate Cancer: the future is here! Current status of Hormone Therapy of ProstateCancer. Focal treatment of Prostate Cancer: current andemerging technologies. Compendium of Guidelines AUA/ EAU 2017 for the management of
Made with FlippingBook flipbook maker